JP2002508766A - 心不全の治療方法 - Google Patents
心不全の治療方法Info
- Publication number
- JP2002508766A JP2002508766A JP50505699A JP50505699A JP2002508766A JP 2002508766 A JP2002508766 A JP 2002508766A JP 50505699 A JP50505699 A JP 50505699A JP 50505699 A JP50505699 A JP 50505699A JP 2002508766 A JP2002508766 A JP 2002508766A
- Authority
- JP
- Japan
- Prior art keywords
- dose
- inotropic
- positive
- heart failure
- adrenergic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5067497P | 1997-06-25 | 1997-06-25 | |
| US60/050,674 | 1997-06-25 | ||
| PCT/US1998/013442 WO1998058638A1 (en) | 1997-06-25 | 1998-06-24 | Method of treating heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002508766A true JP2002508766A (ja) | 2002-03-19 |
| JP2002508766A5 JP2002508766A5 (cg-RX-API-DMAC7.html) | 2005-12-08 |
Family
ID=21966696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50505699A Pending JP2002508766A (ja) | 1997-06-25 | 1998-06-24 | 心不全の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5998458A (cg-RX-API-DMAC7.html) |
| EP (1) | EP1017376A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002508766A (cg-RX-API-DMAC7.html) |
| AU (1) | AU731656B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2295094A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998058638A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020503356A (ja) * | 2017-01-03 | 2020-01-30 | カルディオキシル ファーマシューティカルズ,インク. | ニトロキシル供与性化合物の投与方法 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
| FI20011464A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon |
| US7020521B1 (en) | 2002-11-08 | 2006-03-28 | Pacesetter, Inc. | Methods and apparatus for detecting and/or monitoring heart failure |
| JP2007511487A (ja) | 2003-11-17 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼiv阻害剤の使用 |
| US20060018970A1 (en) * | 2003-12-12 | 2006-01-26 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| JP2007530566A (ja) * | 2004-03-22 | 2007-11-01 | ミオゲン インコーポレイティッド | (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用 |
| EP1737448A1 (en) * | 2004-03-22 | 2007-01-03 | Myogen, Inc. | (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases |
| US20060292213A1 (en) * | 2004-06-23 | 2006-12-28 | Myogen, Inc. | Enoximone formulations and their use in the treatment of PDE-III mediated diseases |
| CN104644627A (zh) | 2004-09-14 | 2015-05-27 | 科罗拉多大学董事会 | 基于基因靶向使用布新洛尔的治疗方法 |
| CA2610022A1 (en) | 2005-06-06 | 2006-12-14 | Georgetown University | Compositions and methods for lipo modeling |
| WO2007014029A2 (en) * | 2005-07-22 | 2007-02-01 | The Regents Of The University Of Colorado, A Body Corporate | Yin yang 1 as a treatment for cardiac hypertrophy and heart failure |
| WO2011032088A1 (en) | 2009-09-11 | 2011-03-17 | Arca Biopharma, Inc. | Polymorphisms in the pde3a gene |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| EP4146215A4 (en) * | 2020-05-04 | 2024-05-01 | Imbria Pharmaceuticals, Inc. | DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE354851B (cg-RX-API-DMAC7.html) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US4405635A (en) * | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
-
1998
- 1998-06-19 US US09/100,497 patent/US5998458A/en not_active Expired - Lifetime
- 1998-06-24 EP EP19980931687 patent/EP1017376A4/en not_active Ceased
- 1998-06-24 WO PCT/US1998/013442 patent/WO1998058638A1/en not_active Ceased
- 1998-06-24 AU AU81740/98A patent/AU731656B2/en not_active Ceased
- 1998-06-24 JP JP50505699A patent/JP2002508766A/ja active Pending
- 1998-06-24 CA CA002295094A patent/CA2295094A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020503356A (ja) * | 2017-01-03 | 2020-01-30 | カルディオキシル ファーマシューティカルズ,インク. | ニトロキシル供与性化合物の投与方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998058638A1 (en) | 1998-12-30 |
| CA2295094A1 (en) | 1998-12-30 |
| EP1017376A4 (en) | 2002-10-25 |
| EP1017376A1 (en) | 2000-07-12 |
| US5998458A (en) | 1999-12-07 |
| AU731656B2 (en) | 2001-04-05 |
| AU8174098A (en) | 1999-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5998458A (en) | Method of treating heart failure | |
| US7829596B2 (en) | Methods of treatment | |
| Zimmerman et al. | Vasopressors and inotropes | |
| JP2022020624A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのnep阻害剤 | |
| Schmitt et al. | Hemodynamic and humoral effects of the novel calcium antagonist Ro 40‐5967 in patients with hypertension | |
| RU2324484C2 (ru) | Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) | |
| Ventetuolo et al. | WHO Group 1 pulmonary arterial hypertension: current and investigative therapies | |
| US8778897B2 (en) | Method of treatment using α-1-adrenergic agonist compounds | |
| JP2018516267A (ja) | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン | |
| TW201302203A (zh) | A2b腺苷受體拮抗劑於在心肌梗塞後之病患內治療心衰竭及心律不整上之用途 | |
| JP2014505106A (ja) | 肺高血圧症を処置するための方法 | |
| Strain et al. | Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure | |
| Oyama et al. | Dose-dependent effects of esmolol-epinephrine combination therapy in myocardial ischemia and reperfusion injury | |
| WO2015069839A1 (en) | Combination therapy for treating pulmonary hypertension | |
| WO2007140181A2 (en) | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist | |
| Goldenberg et al. | New inotropic drugs for heart failure | |
| Wu et al. | Iloprost and exercise haemodynamics in heart failure with preserved ejection fraction—the ILO‐HOPE randomised controlled trial | |
| Malinowski et al. | Next-generation small molecule therapies for heart failure: 2015 and beyond | |
| Watson et al. | Beta2-adrenergic activation via administration of atenolol/formoterol combination increases contractility and coronary blood flow in isolated rat hearts | |
| HUP0201650A2 (hu) | Amino-tetralin-származékok alkalmazása szív- és érrendszeri betegségek gyógykezelésére használható gyógyszerek előállítására | |
| Kiriazis et al. | Chronic activation of the low affinity site of β1‐adrenoceptors stimulates haemodynamics but exacerbates pressure‐overload cardiac remodelling | |
| Van Zwieten | α-Adrenoceptor antagonists | |
| Gwirtz et al. | RESPONSE OF CORONARY BLOOD FLOW TO ALPHA-BLOCKADE DURING SUBMTLXI~ iAL EXERCISE | |
| EA047888B1 (ru) | Применение производных пиперидин мочевины в качестве инотропных агентов | |
| WO2024129057A1 (en) | Methods of treating cardiac injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081112 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090209 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407 |